- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
SANOFI
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Sanofi India Limited · Healthcare · Drug Manufacturers - General
Latest close
3,349 INR
0.9%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -4.0% below the Trend Line and sits at 14.2% of its 52-week range. The latest completed week returned 0.9%, after a -1.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.
Setup score
33
out of 100
Latest Close
3,349 INR
7 Aug 2026
1W Return
0.9%
latest completed week
4W Return
-1.5%
short-term follow-through
12W Return
4.1%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
1.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 36.47% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.9%
Latest completed week; four-week move -1.5%.
Indicator stack
0/70
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 36.47%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
38 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -4.0% below the Trend Line and sits at 14.2% of its 52-week range. The latest completed week returned 0.9%, after a -1.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0912-week average 0.04
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.09Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -1.5% over four weeks, 4.1% over 12 weeks, and -33.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.04Latest activity-pressure read.
Pressure change16.1%Four-week change in activity pressure.
Leadership-13.97Latest relative-leadership reading.
RS change5.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength70/100Blend of value, momentum, and quality. Underlying universe rank 31; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality100/100Profitability and accounting quality. Underlying universe rank 1; rank 1 is best.
Momentum8/100Medium-term price momentum. Underlying universe rank 93; rank 1 is best.
Growth7/100Revenue and earnings growth. Underlying universe rank 94; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework82/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 21.8x Price divided by trailing earnings.
- Price / sales
- 4.2x Market value relative to trailing revenue.
- EV / EBITDA
- 14.4x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 5.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 51.4% Gross profit retained from each unit of revenue.
- Operating margin
- 25.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 22.5% Free cash flow generated from revenue.
- Return on invested capital
- 68.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -8.3% Latest one-year revenue growth.
- EPS growth
- -21.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -3.0% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 8/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 3.7% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 3.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 38 relevant articles.
6 positive · 27 neutral · 5 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-34.8%Distance below the 52-week high.
13-week volatility2.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2616 weeks finished lower.
Best week+7.1%Week of 19 Jun.
Worst week-7.5%Week of 13 Mar.
Latest week+0.9%Week of 7 Aug.
Shape of recent returns
Strong gains2
Modest gains8
Flat weeks0
Modest losses13
Sharp losses3
Recent vol2.7%13-week weekly-return volatility.
Base vol2.6%52-week weekly-return volatility.
Up/down split16/36Count of positive and negative weeks in the 52-week window.
Average skew2.1% / -2.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank64 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - General
4-week rank8 / 11
Group average2.2%
Trend breadth72.7%
Trend72.7%active weekly trend signals
MD81.8%positive activity pressure
RS72.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape29/100
Trend, activity pressure, participation, and risk combine to a 29/100 tape read.
Indicator analysis26/100Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 0/12.
Activity pressure 0.09; No reversal markers Next-Week ExpectancyNegative 36.47%Next-week expectancy is negative with a 36.47% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors61/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 55; Small Cap Core rank 49 SVQF82/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 292.0 of 1593 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment50/100Weighted news tone is neutral across 38 relevant articles.
Why is Sanofi stock slipping today? By Investing.com Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 3,349 INR | 0.9% | 3,490 INR | 5,721 INR | 1.04 | -13.97 | 159.3K | Off |
| 31 Jul 2026 | 3,320 INR | -2.0% | 3,514 INR | 5,743 INR | 1.08 | -14.80 | 211.3K | Off |
| 24 Jul 2026 | 3,389 INR | -0.7% | 3,539 INR | 5,763 INR | 1.03 | -11.67 | 85.7K | Off |
| 17 Jul 2026 | 3,414 INR | 0.4% | 3,561 INR | 5,783 INR | 1.01 | -13.96 | 106.9K | Off |
| 10 Jul 2026 | 3,402 INR | -0.7% | 3,581 INR | 5,803 INR | 0.90 | -14.74 | 143.3K | Off |
| 3 Jul 2026 | 3,425 INR | 2.1% | 3,607 INR | 5,822 INR | 0.60 | -15.25 | 11.9K | Off |
| 26 Jun 2026 | 3,356 INR | 0.4% | 3,636 INR | 5,842 INR | 0.34 | -17.10 | 0 | Off |
| 19 Jun 2026 | 3,341 INR | 7.1% | 3,668 INR | 5,862 INR | 0.11 | -18.20 | 17.7K | Off |
| 12 Jun 2026 | 3,121 INR | -2.1% | 3,705 INR | 5,881 INR | -0.10 | -23.13 | 24.0K | Off |
| 5 Jun 2026 | 3,186 INR | 2.9% | 3,752 INR | 5,902 INR | -0.14 | -21.62 | 9.3K | Off |
| 29 May 2026 | 3,097 INR | -2.1% | 3,798 INR | 5,924 INR | -0.06 | -25.25 | 175.7K | Off |
| 22 May 2026 | 3,163 INR | -1.7% | 3,849 INR | 5,946 INR | 0.03 | -25.12 | 150.0K | Off |
| 15 May 2026 | 3,218 INR | -3.4% | 3,897 INR | 5,967 INR | 0.17 | -24.49 | 129.9K | Off |
| 8 May 2026 | 3,331 INR | -2.2% | 3,941 INR | 5,984 INR | 0.26 | -24.44 | 160.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.